Octant Bio Raises $175M Series B

Drug discovery company using high-throughput screening and machine learning to identify novel therapeutic targets and drug candidates

Key Highlights

Funding Amount: $175M Series B
Valuation: Undisclosed
Headquarters: Emeryville, CA
Founded: 2018
Employees: 100-200
Total Raised: $228M

About the Funding Round

Octant Bio has successfully closed $175M Series B in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

Bain Capital Life Sciences
8VC
Casdin Capital

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Octant Bio achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Octant Bio's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2018 and headquartered in Emeryville, CA, Octant Bio has established itself as an innovative player in the biotech space. With 100-200 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Octant Bio plans to:

Accelerate product development and innovation
Expand into new markets and geographies
Grow the team across engineering, sales, and operations
Strengthen partnerships with key industry players
Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Octant Bio's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.

For more information about Octant Bio, visit their website or contact their press office.

Octant Bio